Introduction: Patients with early HER2-positive breast cancer (BC) benefit from HER2-targeted systemic therapy. The endorsed standard adjuvant treatment for patients with early HER2-positive breast cancer is chemotherapy plus trastuzumab administered for 1 year. Areas covered: Several trials have investigated modifications of the standard treatment in terms of de-escalation by either shortening the duration or giving less resource-demanding regimens and in terms of escalation by either adding a second anti-HER2 agent or extending the duration of HER2-targeted treatment for more than 12 months. In this perspective, we would offer a comprehensive view of these trials and discuss their findings. Expert commentary: At the current state of knowledge, there are still open questions regarding the management of HER2+ BC patients, such as the most adequate duration of trastuzumab therapy, the optimal chemotherapy regimen that should be combined with trastuzumab, and the addition of a second anti-HER2 agent. Growing evidences suggest that some HER2+ BC patients may not need chemotherapy. If these patients could be recognized upfront, optimal response could potentially be reached with HER2-targeted therapy alone.
A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer / A. Esposito, G. Viale, C. Criscitiello, G. Curigliano. - In: EXPERT REVIEW OF CLINICAL PHARMACOLOGY. - ISSN 1751-2433. - 12:1(2019 Jan 02), pp. 9-16.
Titolo: | A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer |
Autori: | VIALE, GIULIA (Secondo) |
Parole Chiave: | Adjuvant trastuzumab duration; breast cancer; HER2-positive breast cancer; HER2-targeted therapy; Pharmacology, Toxicology and Pharmaceutics (all); Pharmacology (medical) |
Settore Scientifico Disciplinare: | Settore MED/06 - Oncologia Medica |
Data di pubblicazione: | 2-gen-2019 |
Rivista: | |
Tipologia: | Article (author) |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1080/17512433.2019.1552134 |
Appare nelle tipologie: | 01 - Articolo su periodico |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
HER2 Curigliano.pdf | Post-print, accepted manuscript ecc. (versione accettata dall'editore) | Open Access Visualizza/Apri |